Microscopic Polyangiitis Clinical Trial
— MAINRITSAN 2Official title:
MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II
Verified date | February 2018 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to assess the efficacy of a rituximab regimen based on rate of ANCA and CD19 lymphocytes for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of two rituximab regimens: one based on ANCA and CD19 lymphocytes versus systematic infusions.
Status | Completed |
Enrollment | 166 |
Est. completion date | April 5, 2016 |
Est. primary completion date | April 5, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic antibodies) at the time of diagnosis or relapse, and at remission. - Who have achieved remission using a treatment combining corticosteroids and an immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the use of another immunosuppressant is allowed, according to the current French guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab). - Interval of 1 month between the end of the immunosuppressant treatment and the randomization time if cyclophosphamide or methotrexate were used, interval between 4 and 6 months if rituximab was used - Age > 18 years without age limit higher when the diagnosis is confirmed. - Informed and having signed the consent form to take part in the study. Exclusion Criteria: - Other systemic vasculitis - Secondary vasculitis (following neoplastic disease or an infection in particular) - Induction treatment with a regimen not corresponding to that recommended in France. - Patient who has not achieved remission. - Incapacity or refusal to understand or sign the informed consent form. - Incapacity or refusal to adhere to treatment or perform the follow-up examinations required by the study. Non-compliance - Allergy, documented hypersensitivity or contraindication to the study medication (cyclophosphamide, corticosteroids, azathioprine, rituximab) - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. - Pregnancy, breastfeeding. Women of childbearing age must use a reliable method of contraception throughout the duration of immunosuppressive treatment up to 1 year after the last infusion of rituximab - Infection by HIV, HCV or HBV - Progressive, uncontrolled infection requiring a prolonged treatment (tuberculosis, HIV infection, etc.). - Severe infection declared during the 3 months before randomization (CMV, HBV, HHV8, HCV, HIV, tuberculosis). - Progressive cancer or malignant blood disease diagnosed during the 5 years before the diagnosis of vasculitis. Patients suffering from non-metastatic prostate cancer or those cured of a cancer or a malignant blood disorder for more than 5 years and not taking any antineoplastic agents for more than 5 years may be included. - Participation in another clinical research protocol during the 4 weeks before inclusion. - Any medical or psychiatric disorder which, in the investigator's opinion, may prevent the administration of treatment and patient follow-up according to the protocol, and/or which may expose the patient to a too greater risk of an adverse effect. - No social security - Churg and Strauss syndrome - Viral, bacterial or fungic or mycobacterial infection uncontrolled in the 4 weeks before the inclusion - History of deep tissue infection (fasciitis, osteomyelitis, septic arthritis)in the first year before the inclusion - History of chronic and severe or recurrent infection or history of preexisting disease predisposing to severe infection - Severe immunodepression - Administration of live vaccine in the four weeks before inclusion - Severe chronic obstructive pulmonary diseases (VEMS < 50 % or dyspnea grade III) - Chronic heart failure stade III and IV (NYHA) - History of recent acute coronary syndrome, unrelated to vasculitis |
Country | Name | City | State |
---|---|---|---|
France | Cochin Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of relapses | Number of relapses (BVAS>0) majors and minors in each group at the end of the maintenance treatment (18 months treatment + 10 months follow-up) | at 28 months | |
Secondary | Number of patients with ANCA (Anti-Neutrophil Cytoplasmatic Antibodies) | Number of patients with ANCA in each group | at 28 months | |
Secondary | Number of adverse events | To assess the number of adverse events and their severity in each group | at 28 months | |
Secondary | Mortality rate | To assess mortality rate in each group | at 28 months | |
Secondary | Number of minor relapse | number of minor relapse in each group | at 28 months | |
Secondary | Cumulated dose of corticosteroid treatment | Cumulated dose of corticosteroid treatment in each group at 28 months | at 28 months | |
Secondary | Number and severity of damages | Number and severity of damages in each group | at 28 months | |
Secondary | Evolution of ANCA and the link of the clinical events | Evolution of ANCA in each group and the link of the clinical events | at 28 months | |
Secondary | Distribution of events by severity | Distribution of events by severity and it will be assigned to the drug and its mode of administration and/or the severity of the disease (in each group). | at 28 months | |
Secondary | Length of corticosteroid treatment | The length of corticosteroid treatment in each group at 28 months | at 28 months | |
Secondary | Rate of B-Lymphocytes CD-19 and the link of the clinical events | The rate of B-Lymphocytes CD-19 and the link of the clinical events | at 28 months | |
Secondary | Evolution of gammaglobulins | at 28 months | ||
Secondary | Quality of life : SF36 (The Short Form (36) Health Survey) | at 28 months | ||
Secondary | Functional capacities : HAQ (Health Assessment Questionnaire) | at 28 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01729624 -
PRO Development for ANCA Associated Vasculitis
|
N/A | |
Terminated |
NCT02474888 -
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
|
||
Active, not recruiting |
NCT02198248 -
Low-dose Glucocorticoid Vasculitis Induction Study
|
Phase 4 | |
Completed |
NCT02190916 -
Vasculitis Illness Perception (VIP) Study
|
N/A | |
Recruiting |
NCT01241305 -
One-Time DNA Study for Vasculitis
|
||
Completed |
NCT00748644 -
Efficacy Study of Two Treatments in the Remission of Vasculitis
|
Phase 3 | |
Recruiting |
NCT02967068 -
VCRC Tissue Repository
|
||
Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Completed |
NCT02190942 -
VCRC Patient Contact Registry Patient-Reported Data Validation Study
|
||
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Terminated |
NCT01586858 -
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
|
N/A | |
Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
Completed |
NCT02190929 -
Educational Needs of Patients With Systemic Vasculitis
|
N/A | |
Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
Completed |
NCT02476292 -
Impact of Vasculitis on Employment and Income
|
N/A | |
Completed |
NCT02169219 -
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
|
Phase 4 | |
Completed |
NCT01613599 -
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
||
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 |